Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) kicked off on Monday, down -1.85% from the previous trading day, before settling in for the closing price of $7.58. Over the past 52 weeks, BCRX has traded in a range of $4.03-$8.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 190.00%. While this was happening, its average annual earnings per share was recorded 65.10%. With a float of $195.87 million, this company’s outstanding shares have now reached $205.77 million.
Considering the fact that the conglomerate employs 536 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 98.3%, operating margin of -15.75%, and the pretax margin is -38.33%.
Biocryst Pharmaceuticals Inc. (BCRX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Biocryst Pharmaceuticals Inc. is 5.32%, while institutional ownership is 82.38%. The most recent insider transaction that took place on Jun 24 ’24, was worth 54,352. In this transaction Director of this company sold 8,600 shares at a rate of $6.32, taking the stock ownership to the 27,831 shares. Before that another transaction happened on Jun 17 ’24, when Company’s Director sold 4,689 for $6.00, making the entire transaction worth $28,134. This insider now owns 27,742 shares in total.
Biocryst Pharmaceuticals Inc. (BCRX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 65.10% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 44.80% during the next five years compared to -3.73% drop over the previous five years of trading.
Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) Trading Performance Indicators
Take a look at Biocryst Pharmaceuticals Inc.’s (BCRX) current performance indicators. Last quarter, stock had a quick ratio of 2.78. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.03.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.73, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.16 in one year’s time.
Technical Analysis of Biocryst Pharmaceuticals Inc. (BCRX)
Compared to the last year’s volume of 3.06 million, its volume of 1.32 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 34.50%. Additionally, its Average True Range was 0.28.
During the past 100 days, Biocryst Pharmaceuticals Inc.’s (BCRX) raw stochastic average was set at 51.68%, which indicates a significant increase from 18.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.46% in the past 14 days, which was lower than the 53.97% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.80, while its 200-day Moving Average is $6.28. Nevertheless, the first resistance level for the watch stands at $7.59 in the near term. At $7.74, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.86. If the price goes on to break the first support level at $7.32, it is likely to go to the next support level at $7.20. Now, if the price goes above the second support level, the third support stands at $7.05.
Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) Key Stats
The company with the Market Capitalisation of 1.54 billion has total of 206,377K Shares Outstanding. Its annual sales at the moment are 331,410 K in contrast with the sum of -226,540 K annual income. Company’s last quarter sales were recorded 109,330 K and last quarter income was -12,670 K.
